# Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

> **NCT02079909** · PHASE2 · COMPLETED · sponsor: **FUJIFILM Toyama Chemical Co., Ltd.** · enrollment: 482 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** T-817MA-H
- **DRUG:** T-817MA-L
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02079909
- **Lead sponsor:** FUJIFILM Toyama Chemical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2017-05-05
- **Final completion:** 2017-05-05
- **Target enrollment:** 482 (ACTUAL)
- **Last updated:** 2019-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02079909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02079909, "Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02079909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*